ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,540Medicare Part D Prescriptions Filled, Including Refills

Rank: 824 out of 3647

$501K Total Retail Price of All Prescriptions

Rank: 1091 out of 3647

527 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
21% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

7% of this provider’s 527 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 10,138 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
SIMVASTATIN 576 548 1 1
LOVASTATIN 508 505 2 21
LISINOPRIL 465 446 3 4
LEVOTHYROXINE SODIUM 430 420 4 5
METOPROLOL TARTRATE 416 398 5 7
AMLODIPINE BESYLATE 325 322 6 2
OMEPRAZOLE 290 271 7 3
FUROSEMIDE 250 246 8 8
WARFARIN SODIUM 225 211 9 15
LISINOPRIL-HYDROCHLOROTHIAZIDE 211 206 10 36
METFORMIN HCL 177 164 11 6
TRAMADOL HCL 164 159 12 22
POTASSIUM CHLORIDE 161 161 13 24
ATENOLOL 155 154 14 10
DIOVAN HCT 142 142 15 80
ADVAIR DISKUS 140 138 16 52
HYDROCHLOROTHIAZIDE 139 136 17 9
ALENDRONATE SODIUM 132 131 18 23
CRESTOR 130 113 19 19
HYDROCODONE-ACETAMINOPHEN 128 128 S3 20 12
PANTOPRAZOLE SODIUM 121 115 21 38
CARVEDILOL 118 107 22 20
AMLODIPINE BESYLATE-BENAZEPRIL 114 111 23 74
DIOVAN 111 98 24 40
AZITHROMYCIN 101 96 25 34
GABAPENTIN 95 93 26 17
METOPROLOL SUCCINATE 95 90 26 18
DIGOXIN 86 86 28 51
DONEPEZIL HCL 84 84 29 30
ATORVASTATIN CALCIUM 84 78 29 13
ZOLPIDEM TARTRATE 82 82 31 14
ENALAPRIL MALEATE 79 77 32 35
PLAVIX 79 79 32 39
TRIAMTERENE-HCTZ 78 78 34 58
CLONIDINE HCL 76 76 35 46
GLIMEPIRIDE 75 75 36 45
GLIPIZIDE 74 74 37 41
GLYBURIDE 70 70 R 38 54
CLOPIDOGREL 65 63 39 26
TAMSULOSIN HCL 64 60 40 28
PAROXETINE HCL 64 52 40 60
ALLOPURINOL 63 63 42 37
CIPROFLOXACIN HCL 62 61 43 53
LOSARTAN POTASSIUM 60 60 44 11
GLIPIZIDE XL 58 56 45 190
GLIPIZIDE ER 56 56 46 112
NAPROXEN 56 56 46 70
SYNTHROID 52 52 48 42
FLUOXETINE HCL 52 52 48 68
KLOR-CON 10 52 52 48 106
JANTOVEN 52 52 48 140
KLOR-CON M10 51 48 52 227
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 18, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.